NOTCH2NL, MYBL2, and UBE2T were reported to be involved in tumorigenesis [36–38], while CXCR4 and IL18R1 were associated with immune response and pathway activation [39, 40], indicating SRSF1 may take part in MM progression via tumor-related pathways. Here, SRSF1 is linked to Miyoshi myopathy.